{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:03:51Z","timestamp":1787943831986,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01389-4","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:10:57Z","timestamp":1761588657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Huaiyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0764-2458","authenticated-orcid":false,"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2343-0436","authenticated-orcid":false,"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1389_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1389_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.27231","volume":"99","author":"Y Abaza","year":"2024","unstructured":"Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, et al. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75\u2009years and older with acute myeloid leukemia: Real-world data from eight US academic centers. Am J Hematol. 2024;99:606\u201314.","journal-title":"Am J Hematol"},{"key":"1389_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193\u2013202.","journal-title":"Am J Hematol"},{"key":"1389_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax\u2009+\u2009hypomethylating agent. Am J Hematol. 2025;100:260\u201371.","journal-title":"Am J Hematol"},{"key":"1389_CR5","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/blood-2022-162525","volume":"140","author":"AT Fathi","year":"2022","unstructured":"Fathi AT, Fell GG, El-Jawahri A, Perl AE, Jonas BA, Dias AL, et al. A phase 2 randomized study comparing venetoclax and azacitidine to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2022;140:3284\u20136.","journal-title":"Blood"},{"key":"1389_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/bloodadvances.2023011219","volume":"8","author":"M Ravindran","year":"2024","unstructured":"Ravindran M, Mozessohn L, Cheung M, Buckstein R, Teichman J. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML. Blood Adv. 2024;8:629\u201339.","journal-title":"Blood Adv"},{"key":"1389_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-4-46","volume":"4","author":"G Wei","year":"2011","unstructured":"Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011;4:46.","journal-title":"J Hematol Oncol"},{"key":"1389_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","volume":"12","author":"E Estey","year":"1994","unstructured":"Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O\u2019Brien S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol : J Am Soc Clin Oncol. 1994;12:671\u20138.","journal-title":"J Clin Oncol : J Am Soc Clin Oncol"},{"key":"1389_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1389_CR10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023;13:2032\u201349.","journal-title":"Cancer Discov"},{"key":"1389_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"1389_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2002-04-1200","volume":"102","author":"A Franzke","year":"2003","unstructured":"Franzke A, Piao W, Lauber JR, Gatzlaff P, Konecke C, Hansen W, et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood. 2003;102:734\u20139.","journal-title":"Blood"},{"key":"1389_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood. 2021;138:234\u201345.","journal-title":"Blood"},{"key":"1389_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, et al. Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol : J Am Soc Clin Oncol. 2022;40:855\u201365.","journal-title":"J Clin Oncol : J Am Soc Clin Oncol"},{"key":"1389_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01389-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T07:02:45Z","timestamp":1761634965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01389-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1389"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01389-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}